Evidera
Evidera provides evidence-based solutions to demonstrate the real-world effectiveness, safety, and value of biopharmaceutical and biotechnology products, offering a wide range of services and boasting over 35 years of industry experience.
Company Overview
Evidera provides evidence-based solutions to demonstrate the real-world effectiveness, safety, and value of biopharmaceutical and biotechnology products. Originally established in 2013, Evidera has over 35 years of leadership in the industry. Acquired by PPD in 2016, the company operates with a workforce of over 750 staff representing more than 45 nationalities and maintains eight primary offices across North America and Europe.
Services
Evidera offers a comprehensive range of services designed to address various needs in the biopharmaceutical and biotechnology sectors. These services include Real-World Evidence & Data Solutions, Non-Interventional Studies, Interventional Studies, Patient-Centered Research, Evidence Synthesis, Modeling & Communication, Strategic Development Consulting, Value & Access Consulting, Medical Writing, and Implementation Science. The company also provides tailored evidence generation strategies spanning regulatory, clinical, and real-world contexts.
Historical Legacy
Evidera has a rich history, with legacy brands including MEDTAP, Caro Research, Abt Bio-Pharmaceutical Solutions, MetaWorks, Total Healthcare Group, and Archimedes. The company has expanded its real-world and patient-centered research capabilities in China, Japan, and beyond through collaborations with HLT and CSS.
Publications and Research
Evidera is highly prolific in its research efforts, having published over 2,400 peer-reviewed articles, with an average of more than 130 articles per year. The company has 1,300+ studies currently in progress across all major therapeutic areas and has supported 150+ drugs/therapies in the past year, including 9 of the top 10 selling drugs in the past five years.
Global Reach and Network
Evidera operates on a global scale, conducting studies in over 70 countries and across 115+ disease areas. The company has executed more than 290 interventional studies in the past five years, involving approximately 113,000+ patients. Evidera's global network includes over 2.2 million healthcare providers, and it has partnered with every one of the top 20 biopharmaceutical companies as well as over 250 small and mid-sized biotechnology companies.